title: Mipomersen sodium: first global approval.
abstract: Mipomersen sodium (Kynamro™) (henceforth mipomersen) is a second-generation antisense oligonucleotide inhibitor of apolipoprotein B-100, which is the main structural component of atherogenic lipid particles. Mipomersen is administered via subcutaneous injection and is indicated as adjunctive treatment for homozygous familial hypercholesterolaemia (HoFH). The drug was developed by Isis Pharmaceuticals, which now collaborates with Genzyme Corporation for on-going development and product marketing. Multinational phase III trials of mipomersen as adjunctive therapy were completed in patients with HoFH, severe FH, heterozygous FH (HeFH) with coronary artery disease (CAD), and in those with hypercholesterolaemia at high risk of CAD. Mipomersen 200 mg once weekly has been approved in the USA as an adjunct to lipid-lowering medications and diet in HoFH patients and is undergoing regulatory review in the EU for the same indication. Genzyme is also conducting a multinational phase III, open-label extension study to evaluate long-term treatment in HoFH and HeFH patients, as well as a multinational trial to evaluate a three-times-per-week mipomersen regimen in patients with severe FH. This article summarises the milestones in the development of once-weekly, subcutaneous mipomersen leading to this first approval.
authors.affiliation: Adis R & D Insight, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754 Auckland, New Zealand. dru@adis.com
authors.forename: Philip
authors.initials: P
authors.lastname: Hair
authors.forename: Fiona
authors.initials: F
authors.lastname: Cameron
authors.forename: Kate
authors.initials: K
authors.lastname: McKeage
mesh_terms: D000818:Animals; D000924:Anticholesteremic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods; D017277:Drug Approval / Q000331:legislation & jurisprudence / Q000379:methods*; D004345:Drug Industry / Q000331:legislation & jurisprudence / Q000639:trends; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy* / Q000453:epidemiology; D020319:Oligodeoxyribonucleotides, Antisense / Q000493:pharmacokinetics / Q000627:therapeutic use*; D009841:Oligonucleotides / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D000924:Anticholesteremic Agents; D020319:Oligodeoxyribonucleotides, Antisense; D009841:Oligonucleotides; C524142:mipomersen
references.citation: Am J Cardiol. 2010 May 15;105(10):1413-9
references.pmid: 20451687
references.citation: Eur Heart J. 2012 Jun;33(12):1451-8
references.pmid: 22634577
references.citation: Circulation. 2012 Nov 6;126(19):2283-92
references.pmid: 23060426
references.citation: Core Evid. 2012;7:29-38
references.pmid: 22701100
references.citation: PLoS One. 2012;7(11):e49006
references.pmid: 23152839
references.citation: Drugs. 2012 Jul 30;72(11):1445-55
references.pmid: 22799743
references.citation: J Am Coll Cardiol. 2010 Apr 13;55(15):1611-8
references.pmid: 20378080
references.citation: Clin Pharmacokinet. 2009;48(1):39-50
references.pmid: 19071883
references.citation: BMJ. 2008 Nov 11;337:a2423
references.pmid: 19001495
references.citation: Circulation. 2008 Aug 12;118(7):743-53
references.pmid: 18663084
references.citation: Eur Heart J. 2011 Nov;32(21):2650-9
references.pmid: 21593041
references.citation: J Clin Lipidol. 2011 Jun;5(3 Suppl):S18-29
references.pmid: 21600526
references.citation: Cardiol Rev. 2012 Mar-Apr;20(2):90-5
references.pmid: 22293857
references.citation: Circulation. 2006 Oct 17;114(16):1729-35
references.pmid: 17030687
references.citation: Eur Heart J. 2012 May;33(9):1142-9
references.pmid: 22507979
references.citation: J Lipid Res. 2010 May;51(5):1057-62
references.pmid: 20008831
references.citation: Lancet. 2010 Mar 20;375(9719):998-1006
references.pmid: 20227758